Nectar Lifesciences Limited — Updates, 08-07-2025: Press Release

Nectar Lifesciences has announced a strategic sale of its core API and formulations business to Ceph Lifesciences for ₹1,270 crore, along with the sale of its menthol business assets for ₹20 crore. This major restructuring aims to streamline operations, reduce debt, invest in emerging sectors, and enhance shareholder value. The transaction underscores Nectar’s shift toward a more focused and innovation-driven business model. Completion is expected by September, subject to shareholder approval.